Integrated Filing — IndAS



General information about company

Scrip Code 543427
NSE Symbol MEDPLUS
MSEI Symbol NOTLISTED
ISIN INE804L01022
Name of company Medplus Health Services Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 20-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 20-05-2026   14:00:00
End date and time of board meeting 20-05-2026   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 1,86,438.50 6,89,246.60
Other income 2,059.50 7,132.40
Total income 1,88,498.00 6,96,379.00
2 Expenses
(a) Cost of materials consumed 2,562.50 8,873.00
(b) Purchases of stock-in-trade 1,39,512.10 5,03,047.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (4,980.20) (3,459.30)
(d) Employee benefit expense 23,811.70 88,452.80
(e) Finance costs 3,348.00 12,049.30
(f) Depreciation, depletion and amortisation expense 7,594.70 28,286.80
(f) Other Expenses
1 Other Expenses 8,615.00 31,596.40
Total other expenses 8,615.00 31,596.40
Total expenses 1,80,463.80 6,68,846.00
3 Total profit before exceptional items and tax 8,034.20 27,533.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 8,034.20 27,533.00
6 Tax expense
7 Current tax 2,239.10 7,766.30
8 Deferred tax (602.20) (2,193.90)
9 Total tax expenses 1,636.90 5,572.40
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,397.30 21,960.60
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 6,397.30 21,960.60
17 Other comprehensive income net of taxes 217.10 217.10
18 Total Comprehensive Income for the period 6,614.40 22,177.70
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 6,398.30 21,964.30
Total profit or loss, attributable to non-controlling interests (1.00) (4.30)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 6,615.40 22,182.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests (1.00) (4.30)
21 Details of equity share capital
Paid-up equity share capital 2,401.10 2,401.10
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 0.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 5.33 18.33
Diluted earnings (loss) per share from continuing operations 5.33 18.29
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.33 18.33
Diluted earnings (loss) per share from continuing and discontinued operations 5.33 18.29
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the Audited consolidated financial results: 1.The above audited consolidated financial results of MedPlus Health Services Limited ('The Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, from time to time. These audited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 20, 2026. These financial results have been audited by the Statutory Auditors of the Company and the auditors have expressed an unqualified opinion on the same. 2.During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000.00 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from December 23, 2021. The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below: Objects as per Prospectus Planned utilisation as per Prospectus Utilisation up to March 31, 2026 Unutilised amount as on March 31, 2026 i)Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements 4,671.70 4,671.70 - ii)General Corporate Purposes 1,117.63 1,117.63 - Total 5,789.33 5,789.33 - 3.During the year ended March 31, 2026, the Central Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the ‘New Labour Codes’, effective from November 21, 2025 primarily impacting the wage definition to be considered for the purpose of defined benefit obligation relating to gratuity and defined benefit contribution relating to leave encashment. As a result of this plan amendment, the Company’s defined benefit obligation and defined benefit contribution increased by Rs. 34.26 and Rs. 31.06 respectively during the year ended March 31, 2026. A corresponding past service cost was recognized in the statement of profit and loss during the current year. The Company continues to monitor the Central / State Rules as notified and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 4.The results for the quarter ended March are the balancing amounts between the figures in respect of the full financial year and the published figures up to the third quarter of the respective financial year. 5.The earnings per equity share for the quarters are not annualised. 6.The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. For and on behalf of the Board of Directors of MedPlus Health Services Limited G. Madhukar Reddy Managing Director & Chief Executive Officer DIN: 00098097 Place: Hyderabad Date: May 20, 2026



Remarks

Debt equity ratio Debt equity ratio of the company is zero, since the company does not have any borrowings as on 31-03-2026
Debt service coverage ratio Debt coverage ratio of the company is zero, since the company does not have any borrowings as on 31-03-2026
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 31,836.10
Capital work-in-progress 3,198.00
Investment property 0.00
Goodwill 4,145.10
Other intangible assets 787.90
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other financial assets 10,441.60
Total of other non-current financial assets 10,441.60
Total non-current financial assets 10,441.60
Deferred tax assets (net) 12,124.80
Other non-current assets
1 Other tax assets (net) 911.00
2 Other non-current assets 259.40
3 Right-of-use assets 1,22,683.70
Total of other non-current assets 1,23,854.10
Total non-current assets 1,86,387.60
2 Current assets
Inventories 1,38,169.40
Current financial asset
Current investments 0.00
Trade receivables, current 2,695.90
Cash and cash equivalents 19,841.20
Bank balance other than cash and cash equivalents 26,375.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 19,779.30
Total current financial assets 68,691.40
Current tax assets (net) 4.20
Other current assets
Total of other current assets
Total current assets 2,06,865.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 3,93,252.60
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,401.10
Other equity 1,95,134.80
Total equity attributable to owners of parent 1,97,535.90
Non controlling interest (70.50)
Total equity 1,97,465.40
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 1,23,312.40
2 Other financial liabilities 185.00
Total of other non-current financial liabilities 1,23,497.40
Total non-current financial liabilities 1,23,497.40
Provisions, non-current 3,360.70
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 1,26,858.10
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 3,074.90
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 27,620.10
Total Trade payable 30,695.00
Other current financial liabilities
1 Lease liabilities 19,125.90
2 Other financial liabilities 7,995.80
Total of other current financial liabilities 27,121.70
Total current financial liabilities 57,816.70
Other current liabilities 5,903.40
1 Other current liabilities 1,795.20
2 Contract liabilities 4,108.20
Total of other current liabilities 5,903.40
Provisions, current 4,926.00
Current tax liabilities (Net) 283.00
Deferred government grants, Current
Total current liabilities 68,929.10
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 1,95,787.20
Total equity and liabilites 3,93,252.60
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Retail 1,82,897.60 6,76,010.60
2 Diagnostic services 3,478.00 13,098.70
3 Others 0.000629 0.001373
Total Segment Revenue 1,86,438.50 6,89,246.60
Less: Inter segment revenue
Revenue from operations 1,86,438.50 6,89,246.60
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Retail 7,052.30 23,881.10
2 Diagnostic services 96.40 174.00
3 Others 42.90 67.20
Total Profit before tax 7,191.60 24,122.30
i. Finance cost 2.00 4.90
ii. Other Unallocable Expenditure net off Unallocable income (844.60) (3,415.60)
Profit before tax 8,034.20 27,533.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Retail 3,10,977.40 3,10,977.40
2 Diagnostic services 13,773.40 13,773.40
3 Others 91.20 91.20
Total Segment Asset 3,24,842.00 3,24,842.00
Un-allocable Assets 68,410.60 68,410.60
Net Segment Asset 3,93,252.60 3,93,252.60
4 Segment Liabilities
Segment Liabilities
1 Retail 1,85,663.10 1,85,663.10
2 Diagnostic services 10,110.00 10,110.00
3 Others 14.10 14.10
Total Segment Liabilities 1,95,787.20 1,95,787.20
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 1,95,787.20 1,95,787.20
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gain on employee benefit plan 269.10 269.10
Total Amount of items that will not be reclassified to profit and loss 269.10 269.10
2 Income tax relating to items that will not be reclassified to profit or loss 52.00 52.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 217.10 217.10



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 27,533.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 4.90
Adjustments for decrease (increase) in inventories (3,659.50)
Adjustments for decrease (increase) in trade receivables, current 0.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,066.20)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (2,481.20)
Adjustments for other financial assets, current (2,575.80)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 28,286.80
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (2,141.10)
Adjustments for provisions, non-current 3,574.20
Adjustments for other financial liabilities, current 1,994.70
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 73.90
Other adjustments for non-cash items 11,760.20
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 33,770.90
Net cash flows from (used in) operations 61,303.90
Dividends received 0.00
Interest paid 0.00
Interest received (4,336.80)
Income taxes paid (refund) 7,409.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 49,558.10
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 1,654.80
Other cash payments to acquire equity or debt instruments of other entities 1,650.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 42.10
Purchase of property, plant and equipment 12,303.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 77,073.10
Purchase of other long-term assets 80,734.80
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 3,146.10
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (12,771.70)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 993.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 26,538.60
Dividends paid 0.00
Interest paid 4.90
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (25,550.50)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 11,235.90
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 11,235.90
Cash and cash equivalents cash flow statement at beginning of period 8,605.30
Cash and cash equivalents cash flow statement at end of period 19,841.20





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 B S R and Co Yes 30-04-2029